Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies

Table 1

Studies of rituximab treatment in idiopathic MPGN. RTX: rituximab, CreaCL: 24 h creatinine clearance, NA: not applicable or not reported, and CR and PR: complete and partial remission (as defined by the authors).

Authors	Study design	(MPGN)	RTX protocol	Renal function	Proteinuria	Outcome
Sugiura et al. [37]	Prospective single-arm ()	1 (idiopathic)	mg/m^2	Creatinine 0.51–1.95 mg/dl (whole cohort)	9.8 g/day	Proteinuria decreased from 9.8 → 1.8 g/day
Dillon et al. [36]	Prospective uncontrolled open-label ()	6 (4 idiopathic, 2 with cryoglobulinemia)	1000 mg on day 1 and on day 15	CreaCl  ml/min/1.73 m^2	g/day	Proteinuria g/day
						CR in patients with cryoglobulinemia
						Stable renal function
Kong et al. [38]	Retrospective case review	2 (idiopathic)	1 × and 2 × 375 mg/m^2	NA	NA	CR and PR